|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 08-18 | Cellectar Biosciences, Inc. - Special Call | |
| 08-13 | Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 21.83M 18.81M 17.81M 16.15M 30.29M 2.09B 30.44M 212M 81.35M 1.06B 82M 80.2M 3.35B | P/E 2026 * |
-0.95x | P/E 2027 * | -1.21x |
|---|---|---|---|---|---|
| Enterprise Value | 21.83M 18.81M 17.81M 16.15M 30.29M 2.09B 30.44M 212M 81.35M 1.06B 82M 80.2M 3.35B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 2.85x |
| Free-Float |
98.25% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Cellectar Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
James Caruso
CEO | Chief Executive Officer | 66 | 2015-06-14 |
Chad Kolean
DFI | Director of Finance/CFO | 60 | 2014-05-27 |
Jarrod Longcor
COO | Chief Operating Officer | 52 | 2022-02-22 |
| Director | Title | Age | Since |
|---|---|---|---|
John Neis
BRD | Director/Board Member | 69 | 2008-01-31 |
James Caruso
BRD | Director/Board Member | 66 | 2015-06-14 |
Douglas Swirsky
CHM | Chairman | 56 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.65% | -2.93% | +47.70% | +86.17% | 994B | |
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | |
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | |
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.95% | 261B | |
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | |
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | |
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | |
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | |
| Average | -0.73% | -5.76% | +22.08% | +40.35% | 389.42B | |
| Weighted average by Cap. | -0.51% | -4.42% | +30.96% | +54.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 7.65M 6.59M 6.24M 5.66M 10.61M 731M 10.66M 74.11M 28.5M 372M 28.73M 28.1M 1.17B |
| Net income | -31.63M -27.25M -25.81M -23.39M -43.88M -3.02B -44.1M -306M -118M -1.54B -119M -116M -4.86B | -37.38M -32.2M -30.49M -27.64M -51.85M -3.57B -52.11M -362M -139M -1.82B -140M -137M -5.74B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
